Where Could Johnson & Johnson's Next Growth Come From?
Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors paying that premium appear to be counting on more growth. The company raised its 2026 guidance on October 13, and Chief Executive Joaquin Duato pointed to one new product as one of its most transformative MedTech innovations. So which product is it.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo